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ABSTRACT 33 
Noonan syndrome (NS) is an autosomal-dominant disorder with variable expressivity and 34 
locus heterogeneity. Despite several RAS pathway genes were implicated in NS, 20-30% 35 
of patients remain without molecular diagnosis, suggesting the involvement of further 36 
genes or multiple mechanisms. Eight patients out of 60, negative for conventional NS 37 
mutation analysis, with heterogeneous NS phenotype were investigated by means of 38 
target resequencing of 26 RAS/MAPK pathway genes. A trio was further characterized 39 
by means of whole exome sequencing. Protein modelling and in silico prediction of 40 
protein stability allowed to identify possible pathogenic RAS pathway variants in four 41 
NS patients. A new c.355T>C variant in LZTR1 was found in patient 43. Two patients 42 
co-inherited variants in LRP1 and LZTR1 (patient 53), or LRP1 and SOS1 genes (patient 43 
67). The forth patient (56) carried a compound heterozygote of RASAL3 gene variants 44 
and also an A2ML1 variant. While these subclinical variants are singularly present in 45 
healthy parents, they co-segregate in patients, suggesting their addictive effect and 46 
supporting a digenic inheritance, as alternative model to a more common monogenic 47 
transmission. The ERK1/2 and SAPK/JNK activation state, assessed on immortalized 48 
lymphocytes from patients 53 and 67 showed highest phosphorylation levels compared 49 
to their asymptomatic parents. These findings together with the lack of their co-50 
occurrence in the 1000Genomes database strengthen the hypothesis of digenic inheritance 51 
in a subset of NS patients. This study suggests caution in the exclusion of subclinical 52 
variants that might play a pathogenic role providing new insights for alternative 53 
hereditary mechanisms.  54 
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INTRODUCTION 55 
Noonan syndrome (NS) is a RASopathy with autosomal-dominant inheritance and 56 
prevalence of 1:1000–2500 (1). NS is characterized by variable expressivity of the 57 
phenotype, including craniofacial features such as hypertelorism, downslanting of the 58 
palpebral fissures, ptosis, low-set, posteriorly rotated ears, and webbed or short neck (1–59 
3). More than 80% of individuals with NS exhibit cardiovascular involvement, most 60 
frequently congenital heart diseases, pulmonary valve stenosis and hypertrophic 61 
cardiomyopathy (4). Other clinical manifestations include cryptorchidism, bleeding 62 
disorders, mild neurocognitive delay and pectus deformity, and an increased risk of 63 
developing myeloproliferative disorders (3,5). Given the considerable variable 64 
expressivity, some NS adults are diagnosed after the birth of an affected child (6,7). 65 
NS shows significant locus and allelic heterogeneity, since variants causing disease, 66 
affecting gene function, involve different genes of the RAS/MAPK (mitogen-activated 67 
protein kinase) signal transduction pathway: PTPN11 (in 40-50% of the patients), SOS1 68 
(10-20%), RAF1 (3-17%), RIT1 (9%), and the less common KRAS, NRAS, BRAF, 69 
SHOC2, MAP2K1, CBL, LZTR1, SOS2, RRAS, CDC42 and A2ML1 (8,9) (1-5%) (9). 70 
The A2ML1 variants have been reported to be associated to few NS patients (10) even if 71 
other authors interpreted one of the two previously reported A2ML1 pathogenic 72 
variants, of unknown significance (VUS) (11). Differently, a significant number of data 73 
evidenced the relevance of functional role of LZTR1 in RAS signaling considering the 74 
effects of its functional variant in NS patients (9,12), Interestingly, the finding of 75 
biallelic LZTR1 pathogenic variants reported in 12 families with NS children, supports 76 
an autosomal recessive inheritance besides the more frequent dominant inheritance 77 
pattern with different implications for the NS pathogenesis ((13)28). Moreover, a few 78 
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NS and NS–like cases have been reported to show Copy Number Variations (CNV) 79 
encompassing NS-associated genes (12,14). However, the pathogenesis remains 80 
unknown in about 20-30% of the patients, pinpointing the need for identifying new 81 
genes or mechanisms responsible for NS pathogenesis (5,15). Interestingly, we have 82 
previously reported a double heterozygous patient carrying both an inherited SOS1 and 83 
a de novo RAF1 variants (7). As the family carriers of that SOS1 variant alone exhibited 84 
a subclinical phenotype, we have hypothesized that the co-expression of additional 85 
subclinical mutant effectors of the RAS pathway may have an addictive effect thus 86 
contributing to the pathogenesis. By means of NGS target approach, we performed the 87 
resequencing of RAS/MAPK pathway genes on eight patients with a clinical diagnosis 88 
of NS and negative for the conventional NS mutation analysis. In three unrelated 89 
patients, we have identified novel affecting function variants in the recently described 90 
LZTR1 NS-gene and in two new identified genes, LRP1 and RASAL3, never associated 91 
with NS. Furthermore, the co-occurrence of sub-clinical variants in two RAS-pathway 92 
genes in the two probands prompted us to propose digenic inheritance as an alternative 93 
pathogenic mechanism occurring in some NS patients, negative to conventional genetic 94 
analysis.  95 
 96 
MATERIALS AND METHODS 97 
Patients and cell samples 98 
Informed consents for genetic studies and publication of case reports were obtained 99 
from all enrolled individuals or parents. Blood samples of these patients had been 100 
collected in the laboratories of the University of Milan mainly from two hospitals, 101 
Fondazione Policlinico San Matteo in Pavia and Istituto Auxologico Italiano in Milan 102 
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The treatment of human subjects complies with the Declaration of Helsinki, and the 103 
Research Ethics Committee of IRCCS Istituto Auxologico Italiano (ID number 104 
08C607_2006) approved the study. Epstein Barr Virus (EBV) immortalized PBMCs, 105 
were provided by Galliera Genetic Bank from patients’ lymphocytes (12) 106 
(Supplementary File). 107 
 108 
Sequencing analysis and quantitative real-time PCR (qPCR) 109 
Constitutional DNA and total RNA were extracted from whole blood according to 110 
standard procedures. PCR was carried out following standard procedures using specific 111 
oligonucleotides (Table S1). The PCR products were sequenced and resolved on an 112 
automated ABI-3130xl DNA genetic analyser (Thermo Fisher). 113 
Total RNA (500 ng) was reverse transcribed using the iScriptTM cDNA Synthesis Kit 114 
(Bio-Rad Laboratories Inc., Barkeley, CA, USA) and specific oligonucleotides allowed 115 
to amplify A2ML1 gene (Table S1), TBP gene was used as a housekeeping control 116 
(Supplementary File). 117 
 118 
NGS analysis and protein modelling  119 
The enrichment of regions of interest was performed using Agilent SureSelect XT 120 
technology. Target resequencing was performed on eight patients’ samples by Illumina 121 
MiSeq platform. Subsequently whole exome sequencing (WES) was performed on a 122 
trio, as the proband was found uncharacterized in the previous analyses. For each 123 
sample, a MiSeq run was performed. Raw reads of NGS data are available in NCBI 124 
Short-read Archive (SRA, https://www.ncbi.nlm.nih.gov/sra/) under accession number 125 
PRJNA607236. 126 
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The detailed bioinformatics analyses applied to NGS data are reported in 127 
Supplementary File. To achieve multiple sequence alignment, necessary for protein 128 
modelling, protein sequences were obtained from Uniprot and the CLUSTAL O servers 129 
were employed. For protein modelling, multiple protein sequences were retrieved from 130 
Uniprot and protein models were obtained through the Swissmodel Target-Template 131 
Alignment module. The final alignments were carried out by means of ClustalO 132 
application (Supplementary File).  133 
 134 
Array comparative genomic hybridization (aCGH) analysis 135 
The aCGH experiments were performed using a commercial SurePrint G3 ISCA 136 
CGH+SNP Microarray Kit, 4x180K slides (Agilent Technologies Inc., Santa Clara, CA, 137 
USA) in accordance with the manufacturer’s instructions. 138 
 139 
Immunoblotting 140 
Proteins were extracted in 7M urea, 2M thiourea, 4%CHAPS, 30mM Tris, 1mM PMSF 141 
(Sigma Aldrich), and 10µl/ml phosphatase inhibitor cocktails A and B (Santa Cruz 142 
Biotechnology). Blots were incubated with anti-SAPK/JNK, anti-phospho SAPK/JNK 143 
(Cell Signaling Technology), anti-ERK1/2 and anti-phosphoERK1/2 (ThermoFisher 144 
Scientific) rabbit polyclonal antibodies (Supplementary File).  145 
 146 
Statistical analysis 147 
The ratio of phosphorylated over the total SAPK/JNK and ERK1/2 band intensity after 148 
western blot was evaluated by applying the ANOVA with post-hoc Tukey HSD 149 
(Honestly Significant Difference) tests (n = 3, p-value < 0.01 or p-value < 0.05). The 150 
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co-occurrence probability of the two SOS1 and LRP1 variants was calculated 151 
considering their minor allele frequency (MAF) in both the whole 1000genomes dataset 152 
and in the European subgroup (503 individuals). We also carried out the Fisher exact 153 
test (http://vassarstats.net/odds2x2.html), and the Peto Odd Ratio (OR) was calculated 154 
for the events of co-occurrence of the two variants in both our cohort of patients and in 155 
the European subgroup of 1000genomes. 156 
 157 
RESULTS 158 
Patients      159 
Eight patients (Pts 43, 49, 53, 55, 56, 62, 67, 69) out of a cohort of 60, negative after 160 
conventional sanger sequence analysis, with or suggestive of NS phenotype, have been 161 
molecularly characterized. The clinical features of the above patients are shown in 162 
Table 1, with the exception of Pt 62, who has been meanwhile diagnosed to have 163 
mosaicism for a small supernumerary marker chromosome derived from chromosome 164 
19 and described by Recalcati et al. (16) as patient 1. Whenever possible, for each of the 165 
clinical feature reported in Table 1 the corresponding item in the HPO (Human 166 
Phenotype Ontology) phenotype vocabulary (17,18) has been indicated. 167 
After the NGS target resequencing, the clinical phenotypes of the patients were 168 
meticulously re-assessed by means of the same clinician. Patients 43, 53, 56 and 67 169 
could be re-evaluated together with their family members, while for patients 49 and 55 170 
only the clinical form filled in during the patients’ enrollment could be revised. Patients 171 
43, 53 and 56 have a clinical diagnosis of NS based on the criteria defined by van der 172 
Burgt e al. (3) and exhibit the typical NS face dysmorphology. Similarly, Pt 69 could be 173 
suggestive for NS diagnosis. Patient 67 instead had been candidate for screening in the 174 
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spectrum of RASopathies due to relative macrocephaly, hypotonia, poor growth and 175 
growth hormone deficiency, congenital heart defect, and after the exclusion of the other 176 
hypothesized clinical conditions. From their clinical records, it can be hypothesized that 177 
Pt. 55, exhibiting hypoplastic supra-orbital ridges and blepharophimosis, may have a 178 
different diagnosis from NS. Similarly, Pt 49 exhibited very few of the typical NS 179 
craniofacial features and a CHD not specific to NS (Table 1). All of the parents and 180 
siblings that could be reviewed (families of Pts 43, 53, 56 and 67, Figure 1) were 181 
confirmed unaffected. Families’ history was unremarkable with the exception of that of 182 
Pt 56: he was the second born fourth child from Moroccan consanguineous parents, as 183 
his paternal grandfather, II-3, and the mother, I-1, of his maternal grandfather, II-4, 184 
were siblings (Figure 1d). The first pregnancy (IV-3) of his mother was reported to 185 
interrupt at the seventh month for polyhydramnios; the second pregnancy (IV-4) was 186 
reported to end at the fourth month of gestation without an apparent reason. The 187 
relatives-clinical records were not available. Both parents were karyotyped to rule out 188 
balanced chromosomal rearrangements. Moreover, the paternal cousin IV-2 was 189 
reported to be affected by hypertrophic cardiomyopathy; the paternal cousin IV-1, who 190 
was born from consanguineous parents too (III-1 and III-2 are cousins), by slight 191 
intellectual disability. Unfortunately, their genotypes, although requested in Morocco, 192 
were not carried out.  193 
 194 
NGS target resequencing 195 
To identify the affecting function variants associated with the clinical condition of the 196 
enrolled patients, we designed a target sequencing panel including genes conventionally 197 
associated with RASopathies, genes recently associated with NS and genes belonging to 198 
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the RAS/MAPK pathway and never associated with RASopathies, for a total of 26 199 
genes (Table S2). We generated 2.9 million reads per sample on average. After 200 
duplicate removal, we obtained an average of 2.8 million reads mapped on NCBI 201 
human reference genome (build GRCh37). The mean depth was 747X (ranging from 202 
384 to 899), with more than 99% of the targeted regions covered by NGS reads in each 203 
sample (Table S3). Only 317 variants passed all the filtering steps imposed by our 204 
pipeline (e.g. low-depth, strand-bias etc.) (Supplementary File). By means of Annovar, 205 
the annotation analysis revealed 312 single-nucleotide polymorphisms (SNPs) and five 206 
deletions. The majority of SNPs occur within intronic regions (114), while the 207 
remaining are located in the 3′UTR or downstream (99), in 5′UTR or upstream (18), in 208 
intergenic regions (20) and in exons (61). Among the coding variants, 16 and 45 are 209 
missense and synonymous respectively (Table S4). Aiming at selecting coding non-210 
silent rare variants in 1000genomes database (1000g2015aug_eur), we applied a 211 
stringent filter, according to a MAF<0,05, obtaining eight rare variants in five genes 212 
(Table 2). To reduce false positive results, we applied a combinatorial approach by 213 
comparing different prediction tools for assessing the possible effects of non-214 
synonymous SNPs (snSNPs) (Table S5). All the selected variants were validated by 215 
Sanger sequencing. No affecting function variants were identified in patients 49, 55, 216 
62 and 69. Chromosomal unbalances were ruled out by aCGH analysis. Proband 43 217 
was found to be a carrier of the novel missense variant c.355T>C (p.(Tyr119His)) in 218 
the exon 4 of LZTR1 (Figure 1a, Table 2). This de novo variant was predicted 219 
deleterious by the majority of in silico tools applied (Table S5). The novel variant 220 
c.1430C>T (p.(Ala477Val)) in the exon 13 of LZTR1, was identified in heterozygosis 221 
in Pt 53 (Table 2; II-2, Figure 1b) and was paternally inherited. The variant was 222 
Formattato: Evidenziato
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number of intergenic regions 
Formattato: Evidenziato
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never reported (Table 2) and was predicted damaging by different in silico tools 223 
(Table S5). Moreover, three maternally inherited LRP1 missense variants were 224 
identified in heterozygosis: c.136C>T (p.(Arg46Trp)), c.5977C>T (p.(Arg1993Trp)), 225 
c.8591G>A (p.(Arg2864His)) (Table 2; II-2, Figure 1b). This gene encodes a member 226 
of the low-density lipoprotein receptor family of proteins, and interacts with FGF 227 
receptors and CBL, mediating its ubiquitination activity involved in RAS pathway 228 
regulation. All these variants were reported as deleterious, in particular the c.5977C>T 229 
(p.(Arg1993Trp)) variant was predicted damaging by all considered tools (Table S5). 230 
The patient 67 showed the paternally inherited variant c.650C>T (p.(Ala217Val)), 231 
rs1800127 (Table 2; II-4, Figure 1c) in the exon 6 of LRP1 predicted as tolerated (Table 232 
S5). This patient also showed the maternally inherited SOS1 variant c.1964C>T 233 
(p.(Pro655Leu)), rs56219475, that was also carried by the unaffected sister II-3 (Figure 234 
1c). The in silico predictions on the effect of this variant were discordant (Table S5), but 235 
the variant was previously reported as benign (6). Given these results, we hypothesized 236 
an addictive effect of the two variants that co-segregate in the proband. At this purpose, 237 
we interrogated 2504 individuals included in the 1000genomes database (phase 3). The 238 
two LRP1 and SOS1 variants display a frequency of 0.00698 and 0.00319 in the 239 
1000genomes database, while in our cohort we detected 0.0199 and 0.0119, 240 
respectively. Furthermore, we assessed if these two variants are never present in the 241 
same individual. We used Fisher exact test to compare the frequency of co-occurrence 242 
in the 1000 genomes EUR (N=503 individuals, no occurrences) and in our sample set 243 
(N=8 patients, 1 co-occurrence), and this difference is statistically significant (p-244 
value=0.015, Peto OR = 5.50). Given the frequency of the two variants, the probability 245 
of co-occurrence in our small sample set (8 patients) is as low as p-value=0.00189, 246 
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suggesting that this event should not be expected in the considered cohort, indicating 247 
that co-occurrence of LRP1 and SOS1 in our cohort with a frequency 0.125 is not a 248 
random event. Furthermore, to verify whether this event is due by chance, we evaluated 249 
in the 1000genomes database the co-occurrence of any two rare variants in all the genes 250 
included in our NGS panel. According to the previous analysis, we retained the non-251 
synonymous variants with a MAF <0.05% and predicted to be damaging by at least two 252 
predictor tools. Following the identification of the individuals carrying more than two 253 
variants, we found that only 16 subjects, out of 2504 individuals (frequency 0.0064), 254 
shared the two variants SOS2 c.1448G>A (p.(Ser483Asn)) and A2ML1 c.1799T>C 255 
(p.(Val600Ala)). The novel missense variant c.2882A>G (p.(Asp961Gly)) in exon 24 of 256 
A2ML1 (Table 2) was found in heterozygosis in patient 56 (Table 2; IV-6, Figure 1d). 257 
The variant was shared with both unaffected consanguineous parents (III-5 and III-6) 258 
and with the unaffected sister (IV-5). In addition, II-3 and II-4, who were reported to be 259 
healthy, are obligate carriers. All these findings suggest that c.2882A>G 260 
(p.(Asp961Gly)) is not sufficient to cause the phenotype (Figure 1d). We, then, 261 
investigated whether differential allelic expression (DAE) in whole blood as well as in 262 
epithelial tissue could be responsible for the incomplete penetrance. No significant 263 
difference of A2ML1 specific alleles expression was observed comparing the proband to 264 
his sibling (data not shown).  265 
 266 
Whole exome sequencing of trio 56  267 
To elucidate the genetic bases of NS in family 56, we hypothesized the involvement of 268 
genes different from those belonging to the RAS pathway and we performed WES in 269 
the trio. At total of 49.11 million reads per sample was obtained; after duplicates 270 
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removal, and an average of 47.03 million reads were mapped on the NCBI human 271 
reference genome (build GRCh37). On average, the mean depth was 37X with more 272 
than 96% of the targeted regions covered by NGS reads in each sample (Table S6). 273 
All the selected variants were validated by Sanger sequencing. The condition of 274 
compound heterozygosis was detected for two variants in RASAL3 gene, encoding a 275 
protein with pleckstrin homology (PH), C2, and Ras GTPase-activation protein 276 
(RasGAP) domains: the c.1963C>A (p.(Gly655Ser)) variant (rs199734851) in the 277 
exon 13 of RASAL3 was paternally inherited, while the c.751C>G (p.(Leu251Val)) 278 
(rs58123634) in exon 7 of the same gene was maternally inherited (Table 2; Figure 1d). 279 
In silico predictions of the deleterious effect of these variants were reported in Table 280 
S5. 281 
 282 
Protein modelling and in silico prediction of protein stability of deleterious 283 
nonsynonymous variants  284 
Sequences of genes with substitutions in encoding regions were analyzed. In detail, 285 
the protein structure of A2ML1, LZTR1, RASAL3, SOS1 and LRP1 were modelled 286 
(see Supplementary File for details). The obtained model of A2ML1 allowed us to 287 
evaluate the c.2882A>G(p.(Asp961Gly)) identified variant. The residue substitution 288 
localizes in the protein core and is not directly involved in post translation 289 
modification (PTMs) or disulfide bridges. The 961 residue seems to have a role in 290 
proteases-binding or in their recognition and the substitution of a charged residue 291 
with a small apolar one may modify the protease binding activity. This substitution 292 
may be destabilizing because it is very close to the typical thiol ester sequence (969-293 
973) (19) involved in the thiol ester bond (970-973) (Figure 2a). Interestingly, this 294 
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sequence is distinctive of the α-Macroglobulin, is involved in protein reactivity (19) 295 
and it is localized on the opposite side of the bait domain on a large binding cavity; 296 
the bait domain is generally cleaved by proteases, in order to induce a conformational 297 
change and entrap the protease itself (19).  298 
The LZTR1 model allowed us the evaluation of the two identified variants (Table 299 
S7): the substitution c.355T>C (p.(Tyr119His)) (Figure 2b) that is predicted to 300 
destabilize the protein structure while the substitution c.1430C>T (p.(Ala477Val)) is 301 
located outside the modelled protein (ending in position 325) portion and is predicted 302 
neutral while (Table S7). Noticeably, His119 in its neutral form can establish π-π 303 
stacking interactions with the neighbor His120, therefore possibly reducing the 304 
flexibility of His121, which interestingly is a catalytic residue. 305 
Concerning to RASAL3, all the three stability prediction tools reported 306 
c.1963G>A(p.(Gly655Ser)) variant as destabilizing for the protein structure (Table 307 
S7). The substituted residue localizes on the protein surface (Figure 2c), within a 308 
loop, at the end of the functional RAS-GAP domain and therefore the substitution 309 
could be involved in the binding interface with RAS destabilizing this docking.  310 
Considering the variant identified in SOS1 (Table S7), we assessed that the 311 
substitution c.1964C>T (p.(Pro655Leu)) is localized on the protein surface, in a loop, 312 
within the RAS-GEF domain (Figure 2d). Since Proline residues are highly 313 
functional for protein structure also in loop conformations, this variant may be 314 
destabilizing for the protein structure.  315 
The new candidate NS LRP1 gene, it encodes a large protein of about 4500 residues, 316 
mainly composed by LDL-receptor repeated domains (20) and by EGF-like domains, 317 
not equally distributed along the sequence (Figure 3e). Due to the protein length, we 318 
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were not able to obtain a single model for the whole structure, but we obtained four 319 
models not super-posable including residues 1 to 3332 (Figure 3 a-d) (Supplementary 320 
File for details). All of the four identified substitutions of LRP1- c.136C>T 321 
(p.(Arg46Trp)), c.650C>T (p.(Ala217Val)), c.5977C>T (p.(Arg1993Trp)) and 322 
c.8591G>A (p.(Arg2864His)) - were predicted to be destabilizing for the protein 323 
structure as indicated by negative difference of free energies of wild type and mutant 324 
structures (Table S7) and were modelled. The first substitution, c.136C>T 325 
(p.(Arg46Trp)) (Figure 3a), is localized in a partially folded region and this 326 
substitution may influence cysteine 65, is involved in a disulfide bridge with Cys48. 327 
The substitution c.650C>T (p.(Ala217Val)) (Figure 3b) is conservative and localizes 328 
on the receptor surface, therefore the involvement in the NS pathogenesis cannot be 329 
ascribable to protein structure destabilization. The substitution c.5977C>T 330 
(p.(Arg1993Trp)) (Figure 3c) displays an increased steric hindrance in a packed 331 
region at the internal side of the YWTD-beta propeller. Moreover, substituting a 332 
positively charged residue with an aromatic nonpolar aminoacid destroys the high 333 
number of hydrogen bonds and salt interactions, which involve Arginine. This 334 
condition induces higher flexibility of the involved protein portion. Furthermore, a 335 
larger sidechain may have effects on the glycosylation of residue Asp1995, necessary 336 
for protein structure. The variant c.8591G>A (p.(Arg2864His)) (Figure 3d) is 337 
localized in a disordered region, but in the nearby of a YWTD-beta propeller. This 338 
type of substitution may be classified as not destabilizing because a positively 339 
charged residue is substituted with another positively charged residue, but with a 340 
lower isoelectric point. However, the variant may influence the disulfide bridge of 341 
residue 2865 with Cys 2884.  342 
15 
 
 343 
Extracellular signal regulated kinase (ERK) and Stress-activation protein 344 
kinase/Jun-amino-terminal kinase (SAPK/JNK) in patients 53 and 67 345 
We carried out specific assays to verify the activation of both ERK1/2 and 346 
SAPK/JNK, thanks to the availability of immortalized lymphoblastoid cell lines 347 
obtained from the PBMCs of both trios 53 and 67, showing a co-segregation of more 348 
hypomorphic variants. In fact, the evaluation of ERK1/2 phosphorylation increase is 349 
a common assay to validate a new NS variant, but more recently a SOS1 variant has 350 
been observed to activate SAPK/JNK instead of ERK in an NS patient (7). While the 351 
levels of ERK1/2 phosphorylation, assessed by immunoblotting, were not 352 
significantly different in patients 53 and 67 compared to their healthy parents and 353 
unrelated controls (Figure 4), SAPK/JNK was activated in both NS patients. The 354 
ratio of the phosphorylated over the total SAPK/JNK band intensities was calculated 355 
for each sample. As expected, the anti-SAPK/JNK antibody revealed two bands at 356 
~46 (p46) and ~54 KDa (p54), respectively (Figure 5a-b). Of them, only p54 resulted 357 
phosphorylated in both patients (Figure 5-d). A statistically significant increment 358 
(ANOVA + Tukey, n =3, p-value < 0.01) of phospho-SAPK/JNK was detected in 359 
sample 67 compared to 67M, 67P and unrelated control (Figure 5e) and in sample 53 360 
compared to 53M, 53P and unrelated control (Figure 5f). In addition, for sample 53, a 361 
second band, p54B, was detected both in total and in phosphorylated SAPK/JNK 362 
blots (Figure 5b).  363 
 364 
DISCUSSION 365 
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Molecular diagnosis remains unknown at least in 20-30% of NS patients (5), 366 
therefore new genes and genetic mechanisms are expected to play a role in the 367 
disease. NGS approach led to the identification of new NS/NS-like genes (4,5,21), all 368 
encoding members of RAS/MAPK pathway. Most of them have been identified in 369 
less than 10 individuals (4), suggesting that all RAS/MAPK genes should be 370 
investigated as potentially implicated in the pathogenesis of NS, and more in general 371 
of RASopathies. Accordingly, we designed an extensive NGS target resequencing 372 
panel. A novel de novo missense variant c.355T>C (p.(Tyr119His)) was identified in 373 
LZTR1 in proband 43, who exhibits a typical NS phenotype with mild severity, since 374 
her development, intellectual skills and growth were unremarkable (Table 1). LZTR1 375 
encodes a protein member of the BTB-kelch superfamily. Recently, a significant 376 
amount of data referring to functional role of LZTR1 in RAS signaling and the impact 377 
of these variants on protein function, have been reported (8,22). Yamamoto et al. 378 
identified rare variants of LZTR1 among which (p.(Tyr119Cys)) was reported as a de 379 
novo event occurring with NS phenotype (23). As the substitution here described is 380 
not conservative, involves the same aminoacidic residue previously described (23) 381 
and may affect a nearby catalytic residue, we propose it as a new pathogenic NS-382 
associated variant. Another novel variant in LZTR1 (NM_006767.3): c.1430C>T, 383 
predicted to be deleterious, but inherited from an unaffected father, was identified in 384 
proband 53. This variant could not be modelled and was not associated with NS 385 
phenotype if inherited alone. Nonetheless, in proband 53, we observed that the co-386 
occurrence of LZTR1 (NM_006767.3): c.1430C>T variants with the three LRP1 387 
variants NM_002332.2: c.[136C>T;5977C>T;8591G>A], all inherited from the 388 
unaffected mother (Figure 1b), segregates with NS phenotype. This complex 389 
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condition suggests a digenic inheritance model. LRP1 is involved in intracellular 390 
signaling functions as well as in lipid metabolism. It is a physiological modulator of 391 
the platelet-derived growth factor (PDGF) signaling pathway and can directly interact 392 
with the ubiquitin E3-ligase CBL, already associated with NS (24,25). This evidence 393 
suggests a Sprouty-like role for LRP1 in modulating ubiquitination and endocytosis 394 
of the tyrosine-kinase (Trk) receptors such as PDGFRbeta (26,27). Moreover, LRP1 395 
regulates the A2ML1 activity by promoting its internalization, thus maintaining its 396 
clearance (28). Interestingly, also the proband 67 paternally inherited the LRP1 397 
(NM_002332.2): c.650C>T variant, which was not associated with NS phenotype if 398 
inherited alone. In addition, the proband 67 also maternally inherited the SOS1 399 
(NM_005633.3): c.1964C>T missense variant (Figure 1c). This variant is not rare in 400 
the population and has been previously reported as benign (6), however the Proline 401 
residue is highly functional for the protein structure, therefore the substitution could be 402 
destabilizing for the structure. All the identified LRP1 variants do not seem to be 403 
sufficient to determine the manifestation of NS phenotype, as we observed in both 404 
cases the co-occurrence with LZTR1 (Pt. 53) and SOS1 variants (Pt. 67). While the 405 
LRP1 and SOS1 variants detected in patient 67 are singularly reported in genomes 406 
from 1000genomes data set, interestingly, their co-presence does not occur. Both the 407 
calculation of co-occurrence probability and the application of Fisher exact test and 408 
OR, indicate that the co-presence of the identified subclinical LRP1 and SOS1 409 
variants is expected as a very rare event. The identification of this condition in one 410 
patient of a cohort of eight individuals (frequency 0.125), together with the very low 411 
frequency of the co-occurrence of two any rare variants in the 1000genomes 412 
population (frequency 0.0064), is consistent with its pathogenic significance, 413 
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invoking the hypothesis of a digenic model in NS. Digenic inheritance of subclinical 414 
variants could partially account for pathogenic causes in 30% of diagnosed NS 415 
patients, explaining the lack of identification of affecting function variants in this NS 416 
subgroup (5). This hypothesis is consistent with the increase of phospho-SAPK/JNK 417 
in the PBMCs cell lines of both patients in comparison to those of their parents, who 418 
carried only one of the two mutated genes present in the probands. We observed no 419 
significant changes in ERK1/2 phosphorylation, which is the functional marker 420 
commonly considered to validate NS variants (5). Nevertheless, Longoni and 421 
colleagues reported on the increasing of phospho-SAPK/JNK after overexpression of 422 
SOS1 R497Q variant detected in the father and grandfather of a double heterozygous 423 
NS patient, carrying both SOS1 and RAF1 variants (7), where both proband’s 424 
relatives showed subclinical NS traits. It is, therefore, possible that SAPK/JNK 425 
pathway, which shares some common effectors with ERK1/2 pathway, might also be 426 
involved in NS pathogenesis. We speculate that the co-occurrence of variants in both 427 
LRP1 and in SOS1 or LZTR1 may alter RAS pathway upstream causing 428 
hyperactivation, likely by an addictive effect, of either ERK1/2 or SAPK/JNK in a 429 
specific tissue fashion (29).  430 
Patient 56 shared the A2ML1 (NM_144670.5): c.2882A>G variant with all the 431 
unaffected family members. Segregation of the variant in the family suggests that it 432 
may be not associated with NS, nevertheless, our model predicted a possible effect 433 
on A2ML1 protein function. Indeed, family member IV-1 (Figure 1d), who is 434 
affected by slight intellectual disability, may be homozygous for the above variant in 435 
A2ML1. Because A2ML1 is a protease inhibitor and binds to LRP1, regulating 436 
activation of the MAPK/ ERK cascade, as in the case of LRP1, we hypothesized that 437 
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also this variant in A2ML1 could contribute to alter the physiological modulation of 438 
RAS/MAPK pathway and display NS insurgence in association with variants 439 
occurring in other genes. At this purpose we performed WES analysis in the trio and 440 
found that Pt.56 was a compound heterozygote for RASAL3 (NM_022904.2): 441 
c.[1963C>A]; and c.[751C>G] variants, which were maternally and paternally 442 
inherited, respectively. The finding, as well as a low probability of loss-of-function 443 
intolerance (pLI = 0.00) (30), is suggestive for RASAL3 being involved in NS 444 
pathogenesis according to an autosomal recessive mechanism. Indeed, the experience 445 
of polyhydramnios in the third trimester during the first pregnancy (IV-3, Figure 1d) 446 
of Pt.56’s mother is highly suggestive of NS and of the likely existence of compound 447 
heterozygosity for RASAL3 pathogenic variants at least in IV-3 aborted fetus. 448 
Noteworthy, Pt.56, who exhibited the typical NS gestalt and had a history of 449 
polyhydramnios and hydrops fetalis during pregnancy, showed developmental delay, 450 
severe speech and language delay associated with sensorineural deafness, and 451 
moderate intellectual disability (Table 1). RASAL3 is a Ras GTPase-activating 452 
protein, i.e. RasGAP (31,32) still little characterized. For instance, NKT cells from liver 453 
of RASAL3-deficient mouse treated with α-GalCer have been shown to increase Erk 454 
phosphorylation, suggesting that RASAL3 negatively regulates Ras/Erk signaling  455 
(31,32). Despite this evidence may be encouraging about our finding, we believe that it 456 
should have been fundamental to investigate how a predicted loss of function of a 457 
RasGAP predominantly expressed in cells of hematopoietic lineages (31,32) can result 458 
in a severely/fully expressed NS RASopathy. Unfortunately, PBMCs samples of 459 
family 56 were not available, therefore it was not possible to investigate ERK1/2 or 460 
SAPK/JNK phosphorylation levels. Furthermore, RASAL3 may also perform a Ras-461 
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independent function in neuronal signal transduction. Indeed, despite in the literature 462 
RASAL3 expression is studied in the lymphoid cells, according to BrainSpan 463 
(https://www.brainspan.org/) and GTEx (https://www.gtexportal.org/home/) 464 
databases, the gene is brain expressed prenatally (average level of expression=0.186) 465 
and in infancy (average level of expression=0.208). Moreover, it keeps on being 466 
expressed, at a higher level, during adult life (average level of expression=2375.5) 467 
(33). Further functional studies will be needed to confirm our findings. Here we 468 
provide a first evidence that digenic inheritance may be an alternative mechanism 469 
involved in the etiopathogenesis of NS and RASopathies, as already hypothesized 470 
(7,34). Moreover, we have identified two novel genes, LRP1 and RASAL3, possibly 471 
involved in the etiopathogenesis of NS/RASopathies. In particular, RASAL3, whose 472 
affecting function variants have been identified in a family from a population with a 473 
high rate of inbreeding, represents, after LZTR1, the second gene associated with 474 
autosomal recessive inheritance in NS so far reported (13). Here we have identified 475 
the presence of variants in major genes of the RAS/MAPK pathways in a subgroup of 476 
NS patients selected from a cohort 60 with heterogonous NS phenotypes, but 477 
negative for conventional NS mutation analysis. To gain more confidence in the 478 
proposed alternative hereditary mechanisms, more NS patients and their families 479 
should be investigated by means of NGS approach. This might be instrumental for 480 
the discovery of subclinical variants in functionally related genes that are apparently 481 
benign if inherited alone, but potential pathogenic if co-segregating in a single 482 
patient. 483 
In conclusion, our results together with the growing body of literature, indicate that 484 
the routinely application of massive sequencing techniques is uncovering the 485 
Codice campo modificato
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emerging contribution of hypomorphic variants to the clinical phenotype, unlike the 486 
application of Sanger method that led to interrupt the analysis when an affecting 487 
function variant was detected. Geneticists need to be aware of the complexity of the 488 
genetic characterization and counselling about NS and RASopathies. Therefore, the 489 
revaluation of many monogenic Mendelian conditions characterized by a broad 490 
spectrum of phenotypes, such as NS, may lead to the identification of different 491 
inheritance models, able to explain variable expressivity and incomplete penetrance.  492 
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FIGURE LEGENDS  662 
Figure 1: Pedigrees of NS patients and segregation analysis of the identified 663 
variants. Filled symbols, subjects with NS/NS spectrum; light-dotted filled symbols, 664 
reported to be affected by slight Intellectual disability (d, IV-1) or hypertrophic 665 
cardiomyopathy (d, IV-2); asterisk, members phenotyped and genotyped in the study; 666 
Pt, patient; SA, spontaneous abortion.   667 
 668 
Figure 2: Structural predictions of A2ML1, LZTR1, RASL3, and SOS1. A2ML1 669 
structural prediction, substituted residue, Asp961Gly, is in blue stick and functional 670 
regions are in evidence, thiol ester sequence in pink and bait region in red (a). LZTR1 671 
model and focus on Tyr199His substitution, in grey wild type (wt) residue and in green 672 
the model of Tyr in position 119 (b). RASAL3 model and focus on Gly655Ser 673 
substitution, in grey wt residue and in white Ser in position 655 (c). SOS1 crystal 674 
structure and focus on Pro655Leu substitution, in grey wt residue and in light-blue 675 
Proline in position 655 (d). 676 
 677 
Figure 3: Assembly of LRP1 models and focus on LRP1 variants. Each colour 678 
identifies a partial model, starting and ending residue of each model is labelled. In the 679 
focus the detail of Arg46Trp substitution, in red wild type (wt) Arg and in white Trp 680 
variant (a), of Ala217Val, in red wt Ala and in white Val variant (b), of Arg1993Trp, in 681 
orange wt Arg and in white Trp variant (c) and of Arg2864His, in blue wt Arg and in 682 
white His variant (d). The domains organization is displayed (e), green pentagon 683 
represents EGF domains, green rhombus represents LDL-receptor class A domain, 684 
while in pink are represented YWTD domains. 685 
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Figure 4: Activation ERK1/2 assay. Representative immunoblot images of stress-686 
activated protein kinase (ERK1/2) (a), and phosphorylated ERK1/2 (b). Histograms 687 
show the ratio of phosphorylated over the total ERK1 (p44) band intensity (O.D. = 688 
optical density, mean ± SD) in patient 53 and 67 compared to their parents and 689 
unrelated controls 524 and 548 (c). Histograms show the ratio of phosphorylated over 690 
the total ERK2 (p42) band intensity (O.D. = optical density, mean ± SD) in patient 53 691 
and 67 compared to their parents and unrelated controls 524 and 548 (d). 692 
Phosphorylation levels were not significantly different in patients 53 and 67 compared 693 
to their healthy parents and controls, applying the ANOVA + Tukey HSD tests (n = 3, 694 
significance threshold: p – value < 0.05). 695 
 696 
Figure 5: Activation SAPK/JNK assay. Representative immunoblot images of stress-697 
activated protein kinase/Jun-amino-terminal kinase (SAPK/JNK) (a, b), and 698 
phosphorylated SAPK/JNK (c, d). Histograms show the ratio of phosphorylated over 699 
the total SAPK/JNK band intensity (O.D. = optical density, mean ± SD) in patient 67 700 
(e) and 53 (f) compared to their parents and unrelated controls 524 (e) and 548 (f). 701 
Significant differences are computed applying the ANOVA + Tukey HSD tests (n = 3, 702 
significance threshold: plain lines = p-value < 0.01, dotted lines = p – value < 0.05). 703 
 704 
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